Tirzepatide improves kidney function and cardiovascular outcomes in patients with obesity and heart failure with preserved ejection fraction (HFpEF), regardless of chronic kidney disease status.

An international team of researchers has discovered a natural mechanism that protects the heart from heart failure with preserved ejection fraction (HFpEF), a serious condition in need of effective ...

At one year, patients taking tirzepatide had a 38% lower rate of cardiovascular death or worsening heart failure (defined as worsening heart failure symptoms in addition to hospitalization or the ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year ...

The results from the SUMMIT trial of tirzepatide in obese patients with heart failure with preserved ejection fraction (HFpEF) showed that Lilly's drug cut the risk of cardiovascular mortality and ...

Whereas obesity is a common confounder when interpreting natriuretic peptide values, and the presence of atrial fibrillation has an important influence on pretest probability, other confounders are ...

SUMMIT was the first trial in patients with heart failure with preserved ejection fraction (HFpEF ... like peptide-1 receptor agonist (GLP-1RA) tirzepatide, which is marketed as Mounjaro, on ...